for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Elsevier   (Total: 3039 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

The end of the list has been reached or no journals were found for your choice.
Journal Cover Revista Española de Medicina Nuclear e Imagen Molecular
  [1 followers]  Follow
    
   Full-text available via subscription Subscription journal  (Not entitled to full-text)
   ISSN (Print) 0212-6982
   Published by Elsevier Homepage  [3039 journals]
  • Utilidad de los parámetros analíticos en el manejo de los pacientes
           pediátricos con sospecha de pielonefritis aguda. ¿Es fiable la
           procalcitonina'
    • Authors: L. Bañuelos-Andrío; M. Espino-Hernández; M. Ruperez-Lucas; M.C. Villar-del Campo; C.I. Romero-Carrasco; G. Rodríguez-Caravaca
      Pages: 2 - 6
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): L. Bañuelos-Andrío, M. Espino-Hernández, M. Ruperez-Lucas, M.C. Villar-del Campo, C.I. Romero-Carrasco, G. Rodríguez-Caravaca
      Objetivo Valorar la utilidad de la procalcitonina (PCT) y de otros parámetros analíticos (leucocitos en sangre, proteína C reactiva [PCR]) como indicadores de daño renal agudo en niños tras su primer episodio de infección del tracto urinario febril o afebril (ITU). Material y métodos Se ha realizado un estudio retrospectivo, con obtención de medidas séricas de PCT, PCR y leucocitos en pacientes pediátricos admitidos entre enero de 2009 y diciembre de 2011, con un primer episodio de ITU, objetivando el daño renal agudo mediante gammagrafía renal con 99mTc-DMSA (DMSA) en las primeras 72h después de la admisión. Se ha llevado a cabo un estudio descriptivo de la muestra y un trazado de curvas ROC con cálculo de puntos de corte óptimos para cada parámetro. Resultados Se han incluido 101 pacientes divididos en 2 grupos en función del resultado del DMSA, 64 fueron diagnosticados de pielonefritis aguda (PNA) y 37 de ITU. Las medias de leucocitos en sangre, PCR y PCT fueron significativamente mayores en pacientes con PNA respecto a aquellos con DMSA normal. El área bajo la curva ROC fue de 0,862 para la PCR, 0,774 para leucocitos en sangre y 0,731 para la PCT. El punto de corte óptimo para la PCT fue 0,285ng/ml (sensibilidad 71,4% y especificidad 75%). Conclusión Si bien los niveles medios de fiebre, leucocitos, PCR y PCT estuvieron significativamente más elevados en pacientes con PNA que en los que tenían ITU, la sensibilidad y especificidad de estos parámetros analíticos no permiten predecir la existencia de afectación renal aguda, haciendo imprescindible la realización de una gammagrafía renal con DMSA. Objective To investigate the usefulness of procalcitonin (PCT) and other analytical parameters (white blood cell count [WBC], C-reactive protein [CRP]) as markers of acute renal damage in children after a first febrile or afebrile urinary tract infection (UTI). Methods A retrospective study was conducted on children with a first episode of UTI admitted between January 2009 to December 2011, and in whom serum PCT, CRP and white blood cell count were measured, as well as assessing the acute renal damage with renal scintigraphy with 99mTc-DMSA (DMSA) within the first 72h after referral. A descriptive study was performed and ROC curves were plotted, with optimal cut-off points calculated for each parameter. Results The 101 enrolled patients were divided into two groups according to DMSA scintigraphy results, with 64 patients being classified with acute pyelonephritis (APN), and 37 with UTI. The mean WBC, CRP and PCT values were significantly higher in patients with APN with respect to normal acute DMSA. The area under the ROC curve was 0.862 for PCR, 0.774 for WBC, and 0.731 for PCT. The optimum statistical cut-off value for PCT was 0.285ng/ml (sensitivity 71.4% and specificity 75%). Conclusion Although the mean levels of fever, WBC, CRP, and PCT were significantly increased in patients with APN than in those who had UTI, the sensitivity and specificity of these analytical parameters are unable to predict the existence of acute renal damage, making the contribution by renal D...
      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.05.006
       
  • La estimulación previa con rhTSH mejora la respuesta al tratamiento con
           radioyodo en pacientes con bocio multinodular tóxico de baja captación
    • Authors: M.J. Azorín Belda; A. Martínez Caballero; G.C. Figueroa Ardila; M. Martínez Ramírez; C.A. Gómez Jaramillo; J.I. Dolado Ardit; J. Verdú Rico
      Pages: 7 - 12
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): M.J. Azorín Belda, A. Martínez Caballero, G.C. Figueroa Ardila, M. Martínez Ramírez, C.A. Gómez Jaramillo, J.I. Dolado Ardit, J. Verdú Rico
      Introducción La estimulación con TSH recombinante humana (rhTSH) aumenta la captación tiroidea de yodo, ayudando al tratamiento con radioyodo en el bocio multinodular (BMN) no tóxico. Sin embargo, son escasos los estudios que utilicen rhTSH previo a terapia con radioyodo en el BMN tóxico para controlar la hiperfunción y clínica compresiva. Material y método Se llevó a cabo un estudio prospectivo en pacientes con BMN e hipertiroidismo. Los pacientes se reclutaron de forma consecutiva y se dividieron en un grupo I, estimulados con 0,3mg de rhTSH antes de recibir radioyodo, y un grupo control o grupo II, sin estimulación previa. Se midió función tiroidea, captación tiroidea de radioyodo, peso tiroideo y síntomas compresivos, y se siguió a los pacientes durante 9 meses. Resultados Un total de 16 pacientes (14 mujeres) de edad media 69,7años constituyeron el grupo I y 16 pacientes (12 mujeres) de edad media 70,7años, el grupo II. Tras el estímulo con 0,3mg rhTSH en el grupo I, la captación de 131I a las 24h aumentó un 78,4% y la dosis estimada absorbida, un 89,3%. En el grupo II, la dosis estimada absorbida fue inferior a la del grupo I tras la estimulación con rhTSH (29,8Gy vs. 56,4Gy; p=0,001). A los 9 meses, se había controlado el hipertiroidismo en un 87,5% de pacientes en el grupo I, y en un 56,2% en el grupo II (p=0,049). La reducción media de peso tiroideo fue mayor en el grupo I que en el II (39,3% vs. 26,9%; p=0,017), con una tendencia a la mejoría subjetiva de la clínica compresiva en el grupo I, aunque no significativa. Solo 2 pacientes describieron taquicardias tras la administración de rhTSH, que se resolvieron con beta-bloqueantes. Conclusiones La estimulación con rhTSH a dosis de 0,3mg previa al tratamiento con radioyodo consigue una reducción del tamaño tiroideo y mejoría funcional en pacientes con hipertiroidismo y BMN de baja captación, sin necesidad de ingreso hospitalario. Aim Stimulation with recombinant human thyrotropin (rhTSH) increases thyroid radioiodine uptake, and is an aid to 131I therapy in non-toxic multinodular goitre (MNG). However, there are not many studies using rhTSH prior to 131I in toxic multinodular goitre to improve hyperthyroidism and compressive symptoms. Material and method A prospective study was conducted on patients with MNG and hyperthyroidism. Patients were recruited consecutively and divided into group I, stimulated with 0.3mg of rhTSH before radioiodine therapy, and a control group or group II, without stimulation. Thyroid function, radioiodine thyroid uptake, thyroid weight, and compressive symptoms were measured, and patients were followed-up for 9 months. Results Group I consisted of 16 patients (14 women), with a mean age 69.7 years, and group II with 16 pa...
      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.05.009
       
  • Radioinmunoterapia en el linfoma no Hodgkin, posicionamiento, seguridad y
           eficacia de 90Y-ibritumomab. Experiencia y seguimiento a los 10 años
    • Authors: A. Martínez; M. Martínez-Ramirez; D. Martínez-Caballero; P. Beneit; J. Clavel; G. Figueroa; J. Verdú
      Pages: 13 - 19
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): A. Martínez, M. Martínez-Ramirez, D. Martínez-Caballero, P. Beneit, J. Clavel, G. Figueroa, J. Verdú
      Introducción La radioinmunoterapia (RIT) es uno de los tratamientos dirigidos contra dianas moleculares del linfoma no Hodgkin (LNH). Objetivo Evaluar el posicionamiento de la RIT con 90Y-ibritumomab en pacientes con LNH, así como su seguridad y efectividad. Método Estudio retrospectivo de pacientes con LNH que recibieron RIT con 90Y-ibritumomab. Se evaluaron la concordancia con las guías clínicas, la toxicidad según la clasificación Common Terminology Criteria for Adverse Events (CTCAE) y la efectividad en función de la respuesta al tratamiento y de la supervivencia global (SG) y la supervivencia libre de progresión (SLP). Resultados Se solicitó RIT en 26 pacientes, de los que 21 (11 mujeres, edad media ± desviación estándar 56±10 años) fueron incluidos en el estudio, con la siguiente distribución: LNH folicular 67%, LNH del manto 14%, LNH difuso de células B grandes 9,5% y LNH transformado 9,5%. Se trató a 12 pacientes con LNH refractario, 7 para consolidación de respuesta y 2 para acondicionamiento a trasplante. El 71% de los pacientes presentó efectos adversos, generalmente manejables y transitorios, siendo la trombocitopenia el más frecuente. A los 3-4 meses, se obtuvo una tasa de respuesta global del 76,2% (completa en 71,4% y parcial en 4,8%) y el 19% mostró progresión de su enfermedad. Con una mediana de seguimiento de 70 meses, la SG fue 96±8 y la SLP de 54±11 meses. Conclusiones La RIT presentó una moderada correlación con las guías clínicas y probablemente esté infrautilizada. Los efectos adversos fueron frecuentes, leves y manejables. Los datos muestran una alta tasa de respuesta completa y una prolongación de la SG y la SLP. Introduction Radioimmunotherapy (RIT) is one of the therapies directed against molecular targets in non-Hodgkin's lymphoma (NHL). Objective To evaluate the positioning, safety, and effectiveness of RIT with 90Y-Ibritumomab in NHL patients. Method A retrospective study was conducted on patients with NHL who received RIT with 90Y-Ibritumomab. An evaluation was made of the concordance with clinical guidelines, toxicity as rated by the Common Terminology Criteria for Adverse Events (CTCAE), and effectiveness was assessed based on response to treatment, overall survival (OS), and progression-free survival (PFS). Results RIT was requested in 26 patients, of whom 21 (11 women, mean age 56±10 years) were included in the study, with the following distribution: Follicular NHL, 67%, Mantle NHL, 14%, Diffuse large B-cell NHL, 9.5%, and Transformed NHL 9.5%. Twelve patients with refractory NHL, 7 for consolidation response, and 2 transplant conditioning, were treated. Adverse effects were observed in 71% of patients, which were usually manageable and transient, and with the most common being thrombocyt...
      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.05.004
       
  • The HURRA filter: An easy method to eliminate collimator artifacts in
           high-energy gamma camera images
    • Authors: H. Perez-Garcia; R. Barquero
      Pages: 27 - 36
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): H. Perez-Garcia, R. Barquero
      Purpose The correct determination and delineation of tumor/organ size is crucial in 2-D imaging in 131I therapy. These images are usually obtained using a system composed of a Gamma camera and high-energy collimator, although the system can produce artifacts in the image. This article analyses these artifacts and describes a correction filter that can eliminate those collimator artifacts. Methods Using free software, ImageJ, a central profile in the image is obtained and analyzed. Two components can be seen in the fluctuation of the profile: one associated with the stochastic nature of the radiation, plus electronic noise and the other periodically across the position in space due to the collimator. These frequencies are analytically obtained and compared with the frequencies in the Fourier transform of the profile. A specially developed filter removes the artifacts in the 2D Fourier transform of the DICOM image. This filter is tested using a 15-cm-diameter Petri dish with 131I radioactive water (big object size) image, a 131I clinical pill (small object size) image, and an image of the remainder of the lesion of two patients treated with 3.7GBq (100mCi), and 4.44GBq (120mCi) of 131I, respectively, after thyroidectomy. Results The artifact is due to the hexagonal periodic structure of the collimator. The use of the filter on large-sized images reduces the fluctuation by 5.8–3.5%. In small-sized images, the FWHM can be determined in the filtered image, while this is impossible in the unfiltered image. The definition of tumor boundary and the visualization of the activity distribution inside patient lesions improve drastically when the filter is applied to the corresponding images obtained with HE gamma camera. Conclusion The HURRA filter removes the artifact of high-energy collimator artifacts in planar images obtained with a Gamma camera without reducing the image resolution. It can be applied in any study of patient quantification because the number of counts remains invariant. The filter makes possible the definition and delimitation of small uptakes, such as those presented in treatments with 131I.

      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.06.003
       
  • Pancreatic accessory spleen. False positive with 99mTc-Octreotide
    • Authors: J. Serrano-Vicente; J.R. Infante-Torre; L. García-Bernardo; M. Moreno-Caballero; A. Martínez-Esteve; J.I. Rayo-Madrid
      Pages: 53 - 55
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): J. Serrano-Vicente, J.R. Infante-Torre, L. García-Bernardo, M. Moreno-Caballero, A. Martínez-Esteve, J.I. Rayo-Madrid
      The case is presented on a patient with abdominal pain and suspicion of neuroendocrine tumor in the tail of the pancreas shown in the abdominal CT and MRI. Whole-body scintigraphy and abdominal SPECT/CT with 99mTc-octreotide were performed that showed a nodular lesion partially on the posterior side of the pancreas tail. This nodule showed faint tracer uptake, and was reported as probable neuroendocrine tumor. Partial pancreatectomy and splenectomy were performed, and the histological study identified the lesion as an ectopic spleen. There are similar cases in the literature that match these findings, but this lesion is still frequently diagnosed after performing unnecessary surgery. When an asymptomatic intrapancreatic mass is detected, an accessory spleen should be considered and specific diagnostic techniques should be performed, such as labeled and denatured red blood cell SPECT/CT.

      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.05.003
       
  • Pancreatic accessory spleen and false positive
    • Authors: V. Wiwanitkit
      First page: 56
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): V. Wiwanitkit


      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remnie.2016.07.008
       
  • Un caso infrecuente de doble adenoma paratiroideo evidenciado con
           99mTc-sestaMIBI SPECT/TC
    • Authors: M.D. Martínez-Valle Torres; E. Ramos Moreno; T. Amrani Raissouni; S. Sanz Viedma; A. Delgado Garcia; J.M. Jiménez-Hoyuela Garcia
      Pages: 57 - 58
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): M.D. Martínez-Valle Torres, E. Ramos Moreno, T. Amrani Raissouni, S. Sanz Viedma, A. Delgado Garcia, J.M. Jiménez-Hoyuela Garcia


      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.02.002
       
  • Utilidad de la 18F-FDG PET/cardio-TC en el diagnóstico de endocarditis
           protésica aórtica tardía con absceso periprotésico
    • Authors: S. Aguadé-Bruix; M.N. Pizzi; A. Roque; H. Cuellar Calabria; N. Fernández-Hidalgo; M.T. González Alujas
      Pages: 59 - 60
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): S. Aguadé-Bruix, M.N. Pizzi, A. Roque, H. Cuellar Calabria, N. Fernández-Hidalgo, M.T. González Alujas


      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.06.007
       
  • Tumor fibroso solitario de mama: aportación de la 18F-FDG PET/TC
    • Authors: C. Riola-Parada; A. Jiménez-Ballvé; A. Serrano-Palacio; M.N. Cabrera-Martín; J.M. Brenes-Sánchez; J.L. Carreras-Delgado
      Pages: 61 - 62
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): C. Riola-Parada, A. Jiménez-Ballvé, A. Serrano-Palacio, M.N. Cabrera-Martín, J.M. Brenes-Sánchez, J.L. Carreras-Delgado


      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.01.002
       
  • A potential pitfall in the use of 68Ga-PSMA PET/CT: Anthracosis
    • Authors: T. Elri; M. Aras; Y.S. Salihoglu; R.U. Erdemir; M. Cabuk
      Pages: 65 - 66
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): T. Elri, M. Aras, Y.S. Salihoglu, R.U. Erdemir, M. Cabuk


      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.06.011
       
  • Síndrome de hipotensión intracraneal espontánea: aportación de la
           cisternografía radioisotópica
    • Authors: Marc Sorigue; Edurne Sarrate; Elisa Orna
      Pages: 47 - 48
      Abstract: Publication date: January–February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 36, Issue 1
      Author(s): J.P. Suárez, M.L. Domínguez, M.A. Gómez, J.L. Muñoz
      La hipotensión intracraneal espontánea es un síndrome clínico debido a la pérdida de volumen de líquido cefalorraquídeo, generalmente secundario a su fuga por defectos estructurales de la duramadre espinal. La cisternografía radioisotópica (CR) es una técnica que puede aportar un diagnóstico confirmatorio en este síndrome, principalmente en casos dudosos o de presentación atípica. Estudiamos retrospectivamente 8 pacientes con CR realizada por sospecha de hipotensión intracraneal espontánea con clínica atípica y/o hallazgos no concluyentes en las técnicas de imagen. La CR detectó extravasación paraespinal de líquido cefalorraquídeo en 7 de ellos. Además, se apreciaron signos indirectos de fuga de líquido cefalorraquídeo en los 8 pacientes, consistentes en la presencia precoz del radiotrazador en orina, presencia de actividad de fondo corporal y/o reducción de la cantidad de radiotrazador en cráneo a las 24 h. La CR tuvo un impacto significativo en el diagnóstico de 6 pacientes y en el manejo terapéutico de 4 pacientes. Spontaneous intracranial hypotension is a clinical syndrome caused by a loss of cerebrospinal fluid volume, usually secondary to leaking through structural defects of the spinal dura mater. Radioisotope cisternography (RC) can confirm the diagnosis of spontaneous intracranial hypotension, especially in doubtful or atypical case presentations. A retrospective study was conducted on 8 patients who underwent RC because spontaneous intracranial hypotension was suspected, and they presented with atypical clinical manifestations and/or inconclusive findings in other imaging techniques. RC detected paradural extravasation of cerebrospinal fluid in 7 patients. Moreover, there was indirect evidence of cerebrospinal fluid leaks in all 8 patients (early appearance of radioactivity in the bladder, soft tissue uptake of radioisotope and/or reduction in the amount of radiotracer in the brain at 24hours). RC had a significant impact on the diagnosis of 6 patients, and on the therapeutic management of 4 patients.

      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.medcli.2016.09.022
       
  • Incidental finding of 131I uptake in mesenteric cystic lymphangioma on
           post-therapy 131I SPECT/CT imaging
    • Authors: G. Shao; Y. Zhao; J. Song; S. Li
      Abstract: Publication date: Available online 10 February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): G. Shao, Y. Zhao, J. Song, S. Li


      PubDate: 2017-02-16T14:46:17Z
      DOI: 10.1016/j.remn.2017.01.002
       
  • Acute pulmonary embolism detection with ventilation/perfusion SPECT
           combined with full dose CT: What is the best option?
    • Authors: M. Milà; J. Bechini; A. Vázquez; V. Vallejos; M. Tenesa; A. Espinal; M. Fraile; M. Monreal
      Abstract: Publication date: Available online 6 February 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): M. Milà, J. Bechini, A. Vázquez, V. Vallejos, M. Tenesa, A. Espinal, M. Fraile, M. Monreal
      Aim To compare diagnostic accuracy of Ventilation/Perfusion (V/P) single-photon emission computed tomography (SPECT) combined with simultaneous full-dose CT with a hybrid SPECT/CT scanner versus planar ventilation/perfusion (V/P) SPECT and CT angiography (CTA) in patients suspected with acute pulmonary embolism (PE). Methods Between 2009 and 2011, consecutive patients suspected of acute PE were referred for V/P SPECT/CT (reviewed board approved study). A contrast agent was administered to patients who had no contraindications. Non-contrast V/P SPECT/CT was performed on the remaining patients. All patients were followed-up for at least 3 months. Results A total of 314 patients were available during the study period, with the diagnosis of PE confirmed in 70 (22.29%) of them. The overall population sensitivity and specificity was 90.91% and 92.44%, respectively for V/P SPECT, 80% and 99.15%, respectively, for CTA, and 95.52% and 97.08% for V/P SPECT/CT. SPECT/CT performed better than V/P SPECT (AUC differences=0.0419, P =0.0043, 95% CI; 0.0131–0.0706) and CTA (AUC differences=0.0681, P =0.0208, 95% CI; 0.0103–0.1259)). Comparing imaging modalities when contrast agent could be administered, sensitivity and specificity increased and V/P SPECT/CT was significantly better than CTA (AUC differences=0.0681, P =0.0208, 95% CI; 0.0103–0.1259) and V/P SPECT (AUC differences=0.0659, P =0.0052, 95% CI; 0.0197–0.1121). In case of non-contrast enhancement, there was non-significant increase of specificity. Secondary findings on CT impacted patient management in 14.65% of cases. Conclusion Our study shows that combined V/P SPECT/CT scanning has a higher diagnostic accuracy for detecting acute PE than V/P SPECT and CTA alone. When feasible, V/P SPECT/CT with contrast enhancement is the best option.

      PubDate: 2017-02-10T14:37:16Z
      DOI: 10.1016/j.remn.2016.11.001
       
  • Response assessment in relapsing polychondritis with 18F-FDG PET/CT
    • Authors: T.K. Jain; A. Sood; A. Sharma; R.K. Basher; A. Bhattacharya; B.R. Mittal
      Abstract: Publication date: Available online 26 January 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): T.K. Jain, A. Sood, A. Sharma, R.K. Basher, A. Bhattacharya, B.R. Mittal


      PubDate: 2017-01-28T14:19:26Z
      DOI: 10.1016/j.remn.2016.10.004
       
  • Incidental detection of tracer avidity in meningioma in 68Ga-PSMA PET/CT
           during initial staging for prostate cancer
    • Authors: T.K. Jain; A.G.S. Jois; S. Kumar V; S.K. Singh; R. Kumar; B.R. Mittal
      Abstract: Publication date: Available online 26 January 2017
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): T.K. Jain, A.G.S. Jois, S. Kumar V, S.K. Singh, R. Kumar, B.R. Mittal


      PubDate: 2017-01-28T14:19:26Z
      DOI: 10.1016/j.remn.2016.10.005
       
  • A novel semi-robotized device for high-precision 18F-FDG-guided breast
           cancer biopsy
    • Authors: D. Hellingman; S.C. Teixeira; M.L. Donswijk; E.J. Rijkhorst; L. Moliner; J. Alamo; C.E. Loo; R.A. Valdés Olmos; M.P.M. Stokkel
      Abstract: Publication date: Available online 28 December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): D. Hellingman, S.C. Teixeira, M.L. Donswijk, E.J. Rijkhorst, L. Moliner, J. Alamo, C.E. Loo, R.A. Valdés Olmos, M.P.M. Stokkel
      Purpose To assess the 3D geometric sampling accuracy of a new PET-guided system for breast cancer biopsy (BCB) from areas within the tumour with high 18F-FDG uptake. Materials and methods In the context of the European Union project MammoCare, a prototype semi-robotic stereotactic prototype BCB-device was incorporated into a dedicated high resolution PET-detector for breast imaging. The system consists of 2 stacked rings, each containing 12 plane detectors, forming a dodecagon with a 186mm aperture for 3D reconstruction (1mm3 voxel). A vacuum-assisted biopsy needle attached to a robot-controlled arm was used. To test the accuracy of needle placement, the needle tip was labelled with 18F-FDG and positioned at 78 target coordinates distributed over a 35mm×24mm×28mm volume within the PET-detector field-of-view. At each position images were acquired from which the needle positioning accuracy was calculated. Additionally, phantom-based biopsy proofs, as well as MammoCare images of 5 breast cancer patients, were evaluated for the 3D automated locating of 18F-FDG uptake areas within the tumour. Results Needle positioning tests revealed an average accuracy of 0.5mm (range 0–1mm), 0.6mm (range 0–2mm), and 0.4mm (range 0–2mm) for the x/y/z-axes, respectively. Furthermore, the MammoCare system was able to visualize and locate small (<10mm) regions with high 18F-FDG uptake within the tumour suitable for PET-guided biopsy after being located by the 3D automated application. Conclusions Accuracy testing demonstrated high-precision of this semi-automatic 3D PET-guided system for breast cancer core needle biopsy. Its clinical feasibility evaluation in breast cancer patients scheduled for neo-adjuvant chemotherapy will follow.

      PubDate: 2017-01-04T13:35:19Z
      DOI: 10.1016/j.remn.2016.11.003
       
  • El nomenclátor y unidades relativas de valor como herramientas de
           gestión
    • Authors: M. Mitjavila; D. Becerra
      Pages: 349 - 350
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): M. Mitjavila, D. Becerra


      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remn.2016.06.005
       
  • Contribution of early SPECT/CT to 99mTc-MIBI double phase scintigraphy in
           primary hyperparathyroidism: Diagnostic value and correlation between
           uptake and biological parameters
    • Authors: P. García-Talavera; G. Díaz-Soto; A.A. Montes; J.G. Villanueva; A. Cobo; C. Gamazo; M.Á. Ruiz; M.L. González-Selma
      Pages: 351 - 357
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): P. García-Talavera, G. Díaz-Soto, A.A. Montes, J.G. Villanueva, A. Cobo, C. Gamazo, M.Á. Ruiz, M.L. González-Selma
      Aim To evaluate the value of 99mTc-MIBI double-phase scintigraphy (DPS) and early SPECT/CT in the pre-surgical assessment of patients with primary hyperparathyroidism (PHPT). Also, to calculate the correlation between uptake and some biological parameters. Material and methods Forty patients with PHPT were included: 37 solitary adenomas, 1 hyperplasia, and 2 double adenomas. Fifteen patients had ectopic glands. DPS and early SPECT/CT were acquired in all patients. Ultrasound was performed in 31/40. All patients underwent surgery, intra-operative iPTH measurements, and histopathological examinations. Qualitative DPS uptake was assessed and correlated to pre-surgical calcium, iPTH levels, gland weight, and maximum diameter. Results In the planar study, there were 23 positive cases, 8 doubtful, and 9 negatives. With the SPECT/CT, 8/9 negatives cases were located. All doubtful cases were confirmed as positives. Gland location improved in 16 cases (12 ectopic). DPS+SPECT/CT failed to detect a solitary adenoma and at least one gland in three cases of multiglandular disease (MGD). The sensitivity by patient was: DPS 72.5%, DPS+SPECT/CT 90%, and ultrasound 42%. Ultrasound and scintigraphy (DPS+SPECT/CT) were concordant in 16/31 patients. For the rest of them, scintigraphy proved correct in 14/15, and both techniques failed in one case. There was a significant correlation between level of uptake and iPTH level, gland weight, and maximum diameter. Conclusion Early SPECT/CT improves sensitivity and the locating of parathyroid pathological glands and increases diagnostic confidence. iPTH level, glandular size, and weight are related to the qualitative assessment of 99mTc-MIBI uptake in early DPS.

      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remnie.2016.03.004
       
  • Detección selectiva del ganglio centinela tras administración
           intratumoral del radiotrazador, en pacientes con cáncer de mama tratadas
           con quimioterapia neoadyuvante en relación con el grado de respuesta
           tumoral
    • Authors: R. Díaz-Expósito; L. Martí-Bonmatí; O. Burgués; I. Casáns-Tormo; B. Bermejo-de las Heras; A. Julve-Parreño; A. Caballero-Garate
      Pages: 358 - 364
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): R. Díaz-Expósito, L. Martí-Bonmatí, O. Burgués, I. Casáns-Tormo, B. Bermejo-de las Heras, A. Julve-Parreño, A. Caballero-Garate
      Objetivo Nuestro objetivo fue analizar el rendimiento de la biopsia selectiva del ganglio centinela valorando la detección gammagráfica tras la administración intratumoral del radiofármaco en pacientes con cáncer de mama que recibieron quimioterapia neoadyuvante. Material y métodos Sesenta pacientes con diagnóstico de carcinoma infiltrante de mama, estadios T1-T3, que recibieron tratamiento con quimioterapia neoadyuvante fueron sometidas posteriormente a cirugía mamaria y biopsia del ganglio centinela mediante administración intratumoral del radiofármaco. Resultados Se consiguió la detección gammagráfica de algún ganglio centinela en 55/60 pacientes (91,6%). Cuando se excluyeron los casos con reinyección periareolar del radiofármaco por falta de migración, la detección fue del 70% (42/60). Cuando se comparó la detección o no del ganglio centinela en estas 42 pacientes, no se encontraron diferencias en función de la edad, lateralidad-localización de la lesión, tamaño pre y posquimioterapia, grado histológico del tumor o perfil inmunohistoquímico. Sí existieron diferencias significativas al comparar los grupos según el grado de respuesta patológica del tumor, valorado tanto con el sistema de Miller-Payne (no detección 44,4%-detección 16,7%, p = 0,003) como con el sistema residual cancer burden (72,2%-28,6%, p<0,01). Conclusiones La detección gammagráfica del ganglio centinela tras administración intratumoral del radiofármaco en pacientes con cáncer de mama que recibieron quimioterapia neoadyuvante estuvo por debajo del valor óptimo, siendo necesaria en ocasiones la reinyección periareolar, lo que podría estar en relación con una alteración de las vías de drenaje linfático. Existió una significativa relación inversa entre detección del ganglio centinela y el grado de respuesta patológica tumoral. Purpose Our objective was to analyse the accuracy of the sentinel node biopsy, taking into consideration the scintigraphy detection rate after the intratumoural administration of the radiopharmaceutical in patients with breast cancer who received neoadjuvant chemotherapy. Materials and methods The study included 60 patients with a diagnosis of invasive breast carcinoma, stage T1-T3, who received treatment with neoadjuvant chemotherapy, and were subsequently subjected to breast surgery and sentinel node biopsy after intra-tumour administration of the radiopharmaceutical. Results Scintigraphic detection of some sentinel node was achieved in 55/60 patients (91.6%). When those cases that received a second injection of the radiopharmaceutical, performed peri-areolarly due to a lack of tracer migration, were excluded, the detection rate dropped to 70% (42/60). When the detection of sentinel node, or its absence, was compared in those 42 patients, no differences were found with age, laterality-location of the lesion, size pre- and post-neoadjuvant chemotherapy, histological grade, or immunohistochemical profile. There were significant differences when comparing the groups according to the degree of pathological tumour response, both with the Miller-Payne system (non-detection 44.4%-detection 16.7%, p = 0.003) as well as the residual cancer burden (72.2%-28.6%, p<0.01).
      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remn.2016.04.005
       
  • Papel pronóstico del volumen metabólico tumoral y de la glucólisis
           tumoral total en los estudios 18F-FDG PET/TC de estadificación del
           cáncer localmente avanzado de mama
    • Authors: A. Jiménez-Ballvé; M. García García-Esquinas; O. Salsidua-Arroyo; A. Serrano-Palacio; J.A. García-Sáenz; A. Ortega Candil; M.E. Fuentes Ferrer; C. Rodríguez Rey; J.M. Román-Santamaría; F. Moreno; J.L. Carreras-Delgado
      Pages: 365 - 372
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): A. Jiménez-Ballvé, M. García García-Esquinas, O. Salsidua-Arroyo, A. Serrano-Palacio, J.A. García-Sáenz, A. Ortega Candil, M.E. Fuentes Ferrer, C. Rodríguez Rey, J.M. Román-Santamaría, F. Moreno, J.L. Carreras-Delgado
      Objetivo Conocer si el volumen metabólico tumoral (VMT) y la glucólisis tumoral total (GTT) pueden predecir el riesgo de recurrencia en cáncer localmente avanzado de mama (CLAM). Material y métodos Estudio retrospectivo de pacientes con CLAM tratados con tratamiento neoadyuvante, local y adyuvante; en seguimiento. Se realizó una 18F-FDG PET/TC para estadificar la enfermedad, midiéndose diferentes parámetros metabólicos (VMT, GTT, SUVmáx y SUVmed), tanto en el tumor primario (T) como en los ganglios metastásicos (N) y en el cuerpo entero (CE). Resultados Se incluyeron 40 mujeres entre enero de 2010-2011; seguimiento hasta enero de 2015. Con una mediana de seguimiento de 46 meses el 20% tuvieron recidiva, local (n=2) o a distancia (n=6); fallecieron 3 (38% de aquellas con recidiva y 7,5% del total). EL SUVmáx, VMT y GTT, tanto en T, como N y CE, fue mayor en aquellas que presentaron recidiva. En el T tanto el VMT como la GTT se relacionaron con la recidiva de la enfermedad (p=0,020 y p=0,028, respectivamente), mientras que en la N fue el SUVmáx (p=0,008). Los puntos de corte óptimos para predecir recurrencia fueron: VMT T≥19,3cm3, GTT T≥74,4g y SUVmáx N≥13,8, existiendo 10-12 veces más probabilidad de experimentar progresión tumoral cuando superaban estos umbrales. El grado tumoral fue la única variable clínico-patológica asociada con la recidiva (p=0,035). Conclusiones En este estudio de CLAM los parámetros metabólicos que más se asocian con la tasa de recidiva son el VMT y la GTT en el tumor primario, el SUVmáx en la enfermedad ganglionar regional y los 3 índices PET en el cuerpo entero. Estos parámetros podrían utilizarse en la práctica asistencial para identificar a las pacientes con mayor riesgo. Objective To determine whether metabolic tumour volume (MTV) and total lesion glycolysis (TLG) are able to predict recurrence risk in locally advanced breast cancer (LABC) patients. Material and methods Retrospective study of LABC patients who undertook neoadjuvant, local and adjuvant treatment and follow up. A 18F-FDG PET/CT study for initial staging was performed analysing in this study different metabolic parameters (MTV, TLG, SUVmax and SUVmed) both in the primary tumour (T) as well as in axillary nodes (N) and whole-body (WB). Results Forty females were included between January 2010-2011; follow up until January 2015 was completed. The average follow-up was 46 months. Twenty percent presented recurrence: local disease (n=2) and distant metastasis (n=6); 3 patients died (38% of the patients which recurred and 7.5% from the total). SUVmax, MTV and TLG, in T, N and WB, were higher in those patients with recurrence. The MTV and TLG parameters in the tumour (T) were related to the recurrence rate (P =
      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remn.2016.01.007
       
  • Estudio comparativo en la definición del volumen de tratamiento en
           radioterapia con «Slow TC Scan» vs. 4D PET/TC Scan en estadios iniciales
           de cáncer de pulmón de célula no pequeña
    • Authors: M. Molla; N. Anducas; M. Simó; A. Seoane; M. Ramos; G. Cuberas-Borros; M. Beltran; J. Castell; J. Giralt
      Pages: 373 - 378
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): M. Molla, N. Anducas, M. Simó, A. Seoane, M. Ramos, G. Cuberas-Borros, M. Beltran, J. Castell, J. Giralt
      Objetivos Evaluar el uso de la 4D PET/TC para capturar el movimiento respiratorio en comparación con la «slow»-TC (TCs), en el procedimiento de planificación de radioterapia. Material y métodos Se ha incluido a 25 pacientes diagnosticados de estadio inicial de cáncer de pulmón de célula no pequeña (NSCLC) médicamente inoperable. A cada paciente se le realizó una TCs (4 s/corte) y una 4D PET/TC. La idoneidad de cada técnica en la captura del movimiento respiratorio fue evaluada comparando el volumen definido por cada una de ellas: internal target volumen (ITV) 4D y el ITVslow, con relación a la suma de los volúmenes de la 4D PET/TC y la TCs (ITVsuma). La máxima diferencia entre el volumen definido por cada técnica respecto al volumen suma fue evaluada en una proyección antero-posterior y otra lateral. Resultados Los volúmenes generados con 4D PET/TC consiguen una definición más precisa del ITV que los volúmenes obtenidos con TCs (ITV4D/ITVsuma 78% vs. ITVslow/ITVsuma 63%). En general, los volúmenes de la 4D PET/TC son de mayor tamaño (19,9 vs. 16,3 cc). El ITV4D muestra menor diferencia con el ITVsuma en los ejes cráneo-caudal y antero-posterior respecto al ITVslow y capta el movimiento de forma más exacta. La máxima diferencia observada es de 0,36mm en la 4D PET/TC y de 0,57mm en la TCs en el eje antero-posterior. Conclusiones La planificación con 4D PET/TC en comparación con TCs permite cuantificar el movimiento respiratorio del tumor y mejorar la planificación de radioterapia en estadios iniciales de NSCLC. Objectives To evaluate the use of 4D PET/CT to quantify tumor respiratory motion compared to the «Slow»-CT (CTs) in the radiotherapy planning process. Material and methods A total of 25 patients with inoperable early stage non small cell lung cancer (NSCLC) were included in the study. Each patient was imaged with a CTs (4s/slice) and 4D PET/CT. The adequacy of each technique for respiratory motion capture was evaluated using the volume definition for each of the following: Internal target volume (ITV) 4D and ITVslow in relation with the volume defined by the encompassing volume of 4D PET/CT and CTs (ITVtotal). The maximum distance between the edges of the volume defined by each technique to that of the total volume was measured in orthogonal beam's eye view. Results The ITV4D showed less differences in relation with the ITVtotal in both the cranio-caudal and the antero-posterior axis compared to the ITVslow. The maximum differences were 0.36mm in 4D PET/CTand 0.57mm in CTs in the antero-posterior axis. 4D PET/CT resulted in the definition of more accurate (ITV4D/ITVtotal 0.78 vs. ITVs/ITVtotal 0.63), and larger ITVs (19.9 cc vs. 16.3 cc) than those obtained with CTs. Conclusion Planning with 4D PET/CT in comparison with CTs, allows incorporating tumor respiratory...
      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remn.2016.02.003
       
  • Identification of low variability textural features for heterogeneity
           quantification of 18F-FDG PET/CT imaging
    • Authors: J. Cortes-Rodicio; G. Sanchez-Merino; M.A. Garcia-Fidalgo; I. Tobalina-Larrea
      Pages: 379 - 384
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): J. Cortes-Rodicio, G. Sanchez-Merino, M.A. Garcia-Fidalgo, I. Tobalina-Larrea
      Objective To identify those textural features that are insensitive to both technical and biological factors in order to standardise heterogeneity studies on 18F-FDG PET imaging. Materials and methods Two different studies were performed. First, nineteen series from a cylindrical phantom filled with different 18F-FDG activity concentration were acquired and reconstructed using three different protocols. Seventy-two texture features were calculated inside a circular region of interest. The variability of each feature was obtained. Second, the data for 15 patients showing non-pathological liver were acquired. Anatomical and physiological features such as patient's weight, height, body mass index, metabolic active volume, blood glucose level, SUV and SUV standard deviation were also recorded. A liver covering region of interest was delineated and low variability textural features calculated in each patient. Finally, a multivariate Spearman's correlation analysis between biological factors and texture features was performed. Results Only eight texture features analysed show small variability (<5%) with activity concentration and reconstruction protocol making them suitable for heterogeneity quantification. On the other hand, there is a high statistically significant correlation between MAV and entropy (P <0.05). Entropy feature is, indeed, correlated (P <0.05) with all patient parameters, except body mass index. Conclusions The textural features that are correlated with neither technical nor biological factors are run percentage, short-zone emphasis and intensity, making them suitable for quantifying functional changes or classifying patients. Other textural features are correlated with technical and biological factors and are, therefore, a source of errors if used for this purpose.

      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remnie.2016.04.008
       
  • Osteomalacia hipofosfatémica sintomática secundaria a tratamiento con
           hierro carboximaltosa objetivada con gammagrafía ósea
    • Authors: M.J. Sangrós Sahún; E. Goñi Gironés; A. Camarero Salazar; C. Estébanez Estébanez; M.E. Lozano Martínez
      Pages: 391 - 393
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): M.J. Sangrós Sahún, E. Goñi Gironés, A. Camarero Salazar, C. Estébanez Estébanez, M.E. Lozano Martínez
      El desarrollo de osteomalacia hipofosfatémica se ha relacionado con diversos tratamientos, fundamentalmente antirretrovirales y administración de hierro por vía intravenosa. La frecuencia de la hipofosfatemia hace necesario vigilar el fosfato tras la administración de hierro carboximaltosa. Presentamos el caso de una mujer sin antecedentes de alteración del metabolismo fosfo-cálcico a la que se pautó este tratamiento por anemia debida a hipermenorrea e intolerancia al hierro por vía oral. Comenzó con dolor oligoarticular que se generalizó más tarde, con importante impotencia funcional y cuya relación con la administración por vía intravenosa de hierro fue descubierta cuando los hallazgos gammagráficos junto con la analítica orientaron hacia una osteomalacia hipofosfatémica. Respondió de forma satisfactoria al tratamiento con fosfato como se objetivó clínicamente y en la gammagrafía ósea de control. The development of hypophosphataemic osteomalacia has been linked with several treatments, mainly antiretroviral and intravenous iron administration. The frequency of the hypophosphataemia requires monitoring the phosphate after the administration of iron carboxymaltose. We describe a case of a woman with no calcium-phosphorous metabolism disorder, to whom this treatment was prescribed for anaemia due to menorrhagia and intolerance to oral iron. She started with oligoarticular pain, which was spreading with a significant functional loss. The relationship with the administration of intravenous iron was discovered when scintigraphic findings together with laboratory results led to a diagnosis of hypophosphataemic osteomalacia. The patient responded satisfactorily to treatment with phosphate both clinically and in the follow-up bone scintigraphy.

      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remn.2016.04.006
       
  • 18F-FDG PET/TC y RM funcional en un caso de afasia progresiva primaria
           logopénica cruzada
    • Authors: M.N. Cabrera-Martín; J.A. Matías-Guiu; M. Yus-Fuertes; M. Valles-Salgado; T. Moreno-Ramos; J. Matías-Guiu; J.L. Carreras Delgado
      Pages: 394 - 397
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): M.N. Cabrera-Martín, J.A. Matías-Guiu, M. Yus-Fuertes, M. Valles-Salgado, T. Moreno-Ramos, J. Matías-Guiu, J.L. Carreras Delgado
      La afasia progresiva primaria es un síndrome clínico secundario a la neurodegeneración de las áreas y redes neuronales involucradas en el lenguaje, habitualmente en el hemisferio izquierdo. El término «afasia cruzada» se refiere a una alteración del lenguaje como consecuencia de una lesión del hemisferio cerebral ipsilateral a la mano dominante. Presentamos el caso de una mujer diestra de 75 años con afasia progresiva primaria logopénica, con dificultad para encontrar palabras, de 2 años de evolución. La 18F-FDG PET/TC mostró un hipometabolismo temporoparietal derecho. Se realizó una RM funcional para caracterizar patrones de lateralización del lenguaje. Se observó un patrón de activación similar en ambos hemisferios y una menor activación de la esperada en el giro frontal inferior bilateral. Estos hallazgos apoyan que la afasia progresiva primaria logopénica no debería considerarse como una afectación de inicio en el hemisferio izquierdo, sino un síndrome caracterizado por una neurodegeneración asimétrica con preferencia por áreas y redes neuronales implicadas en el lenguaje. Primary progressive aphasia is a clinical syndrome caused by a neurodegeneration of areas and neural networks involved in language, usually in the left hemisphere. The term “crossed aphasia” denotes an acquired language dysfunction caused by a lesion in the hemisphere ipsilateral to the dominant hand. A case is presented on a 75-year-old right-handed woman with a logopenic variant of primary progressive aphasia with word-finding difficulties of 2 years onset. The 18F-FDG PET/CT showed right temporoparietal hypometabolism. A functional MRI scan was performed during a verb naming task in order to characterise language lateralisation patterns. A similar activation pattern was observed in both hemispheres, with less activation than expected in bilateral inferior frontal gyrus. These findings support that logopenic variant of primary progressive aphasia should not be considered as a neurodegeneration starting in the left brain hemisphere, but as a syndrome characterised by asymmetric neurodegeneration of brain regions and neural networks involved in language.

      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remn.2016.05.002
       
  • PET/CT in giant cell arteritis: High 18F-FDG uptake in the temporal,
           occipital and vertebral arteries
    • Authors: Z. Rehak; J. Vasina; J. Ptacek; T. Kazda; Z. Fojtik; P. Nemec
      Pages: 398 - 401
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): Z. Rehak, J. Vasina, J. Ptacek, T. Kazda, Z. Fojtik, P. Nemec
      18F-FDG PET/CT imaging is useful in patients with fever of unknown origin and can detect giant cell arteritis in extracranial large arteries. However, it is usually assumed that temporal arteries cannot be visualized with a PET/CT scanner due to their small diameter. Three patients with clinical symptoms of temporal arteritis were examined using a standard whole body PET/CT protocol (skull base – mid thighs) followed by a head PET/CT scan using the brain protocol. High 18F-FDG uptake in the aorta and some arterial branches were detected in all 3 patients with the whole body protocol. Using the brain protocol, head imaging led to detection of high 18F-FDG uptake in temporal arteries as well as in their branches (3 patients), in occipital arteries (2 patients) and also in vertebral arteries (3 patients).

      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remnie.2016.03.008
       
  • Mejor rendimiento de la PET/TC con 18F-FDOPA para la detección de
           metástasis de un tumor neuroendocrino del íleon
    • Authors: N. Testart Dardel; F. Montravers; E. Triviño-Ibañez; M. Gauthé; S. Houry; J.N. Talbot
      Pages: 402 - 405
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): N. Testart Dardel, F. Montravers, E. Triviño-Ibañez, M. Gauthé, S. Houry, J.N. Talbot
      Los tumores neuroendocrinos (TNE) son un grupo de tumores muy heterogéneos y de distribución variable, lo que dificulta su localización anatómica. En medicina nuclear, durante décadas se han propuesto diferentes técnicas de imagen PET o SPECT con diversos radiotrazadores para el estudio de estos tumores, no existiendo consenso actualmente sobre la más adecuada, incluso al considerar solamente los TNE digestivos. Presentamos el caso de una mujer de 67 años con un TNE bien diferenciado del íleon en la que se sospechó una recidiva y ninguna técnica de imagen fue capaz de detectar la enfermedad, excepto la PET/TC con 18F-FDOPA. El seguimiento posterior mostró progresión de la enfermedad, confirmándose la positividad de este primer hallazgo. A raíz del caso se discuten y comparan los radiofármacos posibles para el diagnóstico de TNE digestivos, haciendo énfasis en los derivados embriológicamente del intestino medio. Neuroendocrine tumours (NET) are heterogeneous and frequently spread over the body, making their imaging difficult. With this aim, nuclear medicine imaging, using PET or SPECT with different tracers, has been proposed for decades, but there is currently no consensus on the most appropriate technique, even when only considering gastrointestinal NET. The case is presented of a 67year old woman with a well differentiated NET of the ileum with suspected recurrence, which was not detected by any imaging technique except 18F-FDOPA PET/CT. Subsequent follow up showed disease progression, which confirmed the true positivity of 18F-FDOPA. Using this case, we discuss and compare different radiotracers for the diagnosis of gastrointestinal NET, focusing on those embryologically originating from the mid-gut.

      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remn.2016.04.007
       
  • Evaluation of a crossed fused renal ectopia in a paediatric patient using
           99mTc-DMSA SPECT/CT
    • Authors: A. Dehesa; A. Zugazaga; M.B. De Miguel; L. Biassoni
      Pages: 406 - 408
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): A. Dehesa, A. Zugazaga, M.B. De Miguel, L. Biassoni


      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remnie.2016.01.023
       
  • Dual-time-point 18F-FDG-PET/CT imaging of a paravalvular pseudoaneurysm
           after infective endocarditis
    • Authors: B. Rodriguez-Alfonso; I. Zegri; J. Mucientes Rasilla; A. Forteza; D. Petite; A. Ramos Martinez
      Pages: 409 - 410
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): B. Rodriguez-Alfonso, I. Zegri, J. Mucientes Rasilla, A. Forteza, D. Petite, A. Ramos Martinez


      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remnie.2016.04.009
       
  • Co-existence of a giant cell tumour of the tendon sheath and schwannoma in
           a patient with bilateral breast cancer: A potential cause of false
           positive findings in 18F-FDG PET/CT studies
    • Authors: A. Ortega Candil; C. Rodríguez Rey; M. García García-Esquinas; M.N. Cabrera Martín; R. Couto Caro; J.L. Carreras Delgado
      Pages: 411 - 412
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): A. Ortega Candil, C. Rodríguez Rey, M. García García-Esquinas, M.N. Cabrera Martín, R. Couto Caro, J.L. Carreras Delgado


      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remnie.2016.05.002
       
  • A rare case of tonsillar metastatic small cell carcinoma originating from
           the lung assessed by 18F-FDG PET/CT
    • Authors: R. Zhang; Z. Hu; J. Tan; J. Shen
      Pages: 413 - 414
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): R. Zhang, Z. Hu, J. Tan, J. Shen


      PubDate: 2016-11-07T10:03:52Z
      DOI: 10.1016/j.remnie.2016.03.006
       
  • Primary hyperparathyroidism regression associated to cinacalcet therapy
           proved by 99mTc-MIBI scintigraphy
    • Authors: A. Coloma; S. Hernández-Estrada; H. Bowles; N. Sánchez; D. Fuster; J. Torregrosa
      Abstract: Publication date: Available online 20 December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): A. Coloma, S. Hernández-Estrada, H. Bowles, N. Sánchez, D. Fuster, J. Torregrosa


      PubDate: 2016-12-27T13:24:04Z
      DOI: 10.1016/j.remn.2016.10.010
       
  • Oncocytoma as a growing FDG-avid adrenal mass on serial 18F-FDG PET/CT
           imaging: A potential pitfall in oncological evaluation
    • Authors: L. Gilardi; M. Vadrucci; S. Pirola; C.M. Grana
      Abstract: Publication date: Available online 13 December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): L. Gilardi, M. Vadrucci, S. Pirola, C.M. Grana


      PubDate: 2016-12-20T13:13:29Z
      DOI: 10.1016/j.remn.2016.10.007
       
  • A propósito de un caso de miopatía inflamatoria. Cuantificación de la
           inflamación muscular mediante PET/TC con 18F-FDG en la evaluación
           inicial y la respuesta terapéutica
    • Authors: J.R. García; A. Jaramillo; E. Iglesias; E. Inarejos; C. Jou; E. Riera
      Abstract: Publication date: Available online 13 December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): J.R. García, A. Jaramillo, E. Iglesias, E. Inarejos, C. Jou, E. Riera


      PubDate: 2016-12-20T13:13:29Z
      DOI: 10.1016/j.remn.2016.10.009
       
  • Gammagrafía de tránsito gastrointestinal en el estudio del
           
    • Authors: J.R. Infante; J.I. Rayo; J. Serrano; L. García; M. Moreno; A. Martínez; J. Huertas
      Abstract: Publication date: Available online 10 December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): J.R. Infante, J.I. Rayo, J. Serrano, L. García, M. Moreno, A. Martínez, J. Huertas
      Objetivo El estreñimiento crónico es una enfermedad común en el niño. Nuestro objetivo fue poner de manifiesto la utilidad de la gammagrafía de tránsito gastrointestinal en el estudio de pacientes pediátricos con estreñimiento crónico y las ventajas que tiene respecto a otros estudios de imagen, a pesar de nuestra limitada experiencia. Material y métodos Se valoraron 5 pacientes remitidos a nuestro servicio con diagnóstico de estreñimiento crónico refractario al tratamiento. Se realizó un protocolo de estudio completo, incluyendo gammagrafía de vaciamiento gástrico para líquidos y tránsito de intestino delgado y grueso, utilizándose una única dosis de 111In-DTPA. Siguiendo guías internacionales se definieron áreas de interés en estómago, íleon terminal y en 6 regiones del intestino grueso. Resultados Todos los enfermos presentaron estudios gammagráficos alterados, mostrando 4 de ellos exploraciones radiológicas normales. El estudio radioisotópico cambió el diagnóstico del paciente en 2 casos y en otros 2 contribuyó a aclararlo, ante la discordancia entre pruebas radiológicas normales y biopsia rectal patológica. Uno de los pacientes mostró concordancia entre los 2 estudios de imagen. Tras la gammagrafía se produjo cambio en el manejo terapéutico en 2 casos. Conclusiones Nuestra limitada experiencia coincide con los datos publicados en los que el estudio gammagráfico resulta ser un método reproducible y preciso. Proporciona una información fisiológica, cuantitativa y útil en el estudio del estreñimiento, siendo la única exploración que permite la determinación tanto global como regional del tiempo de tránsito gastrointestinal. Aim Chronic constipation is a common pathology in children. The aim of this paper was to show the usefulness of gastrointestinal transit scintigraphy in pediatric patients with chronic constipation, and the advantages with respect to other imaging techniques, despite our limited experience. Material and methods We evaluated 5 patients sent to our service with a diagnosis of chronic constipation refractory to treatment. We performed a complete study protocol, including liquid gastric emptying scintigraphy and small and large bowel transit times, using a single dose of 111In-DTPA. Following international guidelines regions of interest were defined in stomach, terminal ileum and in 6 regions of the large intestine. Results All patients showed altered scintigraphy study, showing 4 of them normal radiological tests. Radioisotopic study changed diagnosis in 2 patients and in other 2 patients contributed to clarify it, since discordance between normal radiological tests and abnormal rectal biopsy. One of the patients showed concordance between each imaging modality. The results of the test changed the therapeutic management in 2 cases. Conclusions Our limited experience coincides with published data in which scintigraphy study turns out to be a reproducible and accurate method. It provides physiological, quantitative and useful information in the study of constipation, being the unique exploration that allows both global and regional gastrointestinal transit tim...
      PubDate: 2016-12-12T11:02:32Z
      DOI: 10.1016/j.remn.2016.10.011
       
  • Unexpected primary bone lymphoma
    • Authors: S. Rodríguez Martínez de Llano; M.L. Poncet Souto; R. Álvarez Rodríguez; C. Lancha Hernández; I. Candal Casado; P. Pais Silva
      Abstract: Publication date: Available online 6 December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): S. Rodríguez Martínez de Llano, M.L. Poncet Souto, R. Álvarez Rodríguez, C. Lancha Hernández, I. Candal Casado, P. Pais Silva


      PubDate: 2016-12-12T11:02:32Z
      DOI: 10.1016/j.remn.2016.10.006
       
  • Nuevos tiempos para los grupos de trabajo de la SEMNIM
    • Authors: Arbizu
      Abstract: Publication date: Available online 2 December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): J. Arbizu


      PubDate: 2016-12-05T10:51:54Z
       
  • Eficacia de los análogos de somatostatina radiomarcados (90Y-DOTATOC y
           177Lu-DOTATATE) en pacientes con tumores neuroendocrinos metastásicos,
           experiencia de centro único en México
    • Authors: S.S. Medina-Ornelas; F.O. García-Pérez
      Abstract: Publication date: Available online 24 November 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): S.S. Medina-Ornelas, F.O. García-Pérez
      Objetivo Determinar la eficacia de la terapia con análogos de somatostatina radiomarcados 90Y-DOTATOC y 177Lu-DOTATATE en el tratamiento de tumores neuroendocrinos metastásicos con progresión después de la primera línea de tratamiento. Material y métodos Se estudiaron 30 pacientes con el diagnóstico con tumor neuroendocrino (gastroenteropancreático, broncopulmonar, MEN2A, MEN2B, feocromocitoma y paraganglioma) con enfermedad metastásica diagnosticados por el departamento de patología, con progresión después de la primera línea de tratamiento, reclutados de diciembre del 2014 a febrero del 2016. La eficacia fue analizada usando la TC siguiendo los criterios RECIST 1.1 y los cambios moleculares en el SUVmáx de la PET/TC con 68Ga-DOTATOC. La seguridad fue valorada mediante el renograma con 99mTc-MAG3. Resultados Los 30 pacientes recibieron un total de 49 ciclos de 90Y-DOTATOC (21 dosis) y 177Lu-DOTATATE (28 dosis), con una media de 1,5 ciclos por paciente; 17 (56,7%) mostraron respuesta morfológica parcial; 22 (73,3%) respuesta molecular y bioquímica, y 23 (76,6%) respuesta clínica. Durante la mediana de seguimiento (13 meses) un paciente falleció (3,4%). La mediana de supervivencia global desde el diagnóstico fue de 54 meses (IC 95%, 31,18-76,81), y la mediana de supervivencia libre de progresión fue de 32 meses (IC 95%, 15,00-48,99). Conclusión El tratamiento con 90Y-DOTATOC y 177Lu-DOTATATE es una terapia prometedora para los pacientes con tumores neuroendocrinos bien y moderadamente diferenciados. La eficacia es proporcional al número de ciclos administrados, inversamente proporcional al número de metástasis (<10) y en relación con el grado de captación conforme al SUVmáx por parte de las metástasis, independientemente del volumen tumoral metabólicamente activo. Objective To determine the effectiveness of therapy with the radiolabelled somatostatin analogues, 90Y-DOTATOC and 177Lu-DOTATATE, in the treatment of metastatic neuroendocrine tumours with progression to first-line treatment. Material and methods A study was conducted on 30 patients diagnosed with neuroendocrine tumours (gastroenteropancreatic, bronchopulmonary, MEN2A, MEN2B, phaeochromocytoma, and paraganglioma) with metastatic disease diagnosed by the pathology department, with progression to first-line treatment, and recruited from December 2014 to February 2016. Efficacy was analysed using computed tomography (CT) according RECIST 1.1 criteria, and the molecular changes using the SUVmax of PET/CT with 68Ga-DOTATOC. Safety was carried out with a renal scan with 99mTc-MAG3. Results The 30 patients received a total of 49 cycles 90Y-DOTATOC (21 doses) and 177 Lu-DOTATATE (28 doses), with a mean of 1.5 cycles per patient. Of these, 17 (56.7%) showed a partial morphological response, 22 (73.3%) molecular and biochemical response, and 23 (76.6%) clinical response. One patient died during the median follow-up of 13 months. The median overall survival from diagnosis was 54 months (95% CI; 31.18-76.81), and median progression-free survival was 32 months (95% CI; 15.00-48.99).
      PubDate: 2016-11-28T10:38:50Z
      DOI: 10.1016/j.remn.2016.09.005
       
  • Tratamiento con 177LU-DOTATATE en tumores neuroendocrinos. Estudio
           preliminar
    • Authors: I. Hervás; P. Bello; M. Falgas; M.I. del Olmo; I. Torres; C. Olivas; V. Vera; P. Oliván; A.M. Yepes
      Abstract: Publication date: Available online 23 November 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): I. Hervás, P. Bello, M. Falgas, M.I. del Olmo, I. Torres, C. Olivas, V. Vera, P. Oliván, A.M. Yepes
      La terapia con péptidos análogos de la somatostatina marcados con radionúclidos es un nuevo tratamiento prometedor para tratar tumores neuroendocrinos. El objetivo del presente estudio preliminar es presentar nuestra experiencia en la terapia con 177Lu-DOTATATE y evaluar la tolerabilidad y la eficacia a corto plazo en pacientes con tumores que expresan receptores para la somatostatina. Se han tratado 7 pacientes con tumores neuroendocrinos metastásicos, cada uno con 4 dosis de 177Lu-DOTATATE y se ha evaluado su respuesta al tratamiento en forma de respuesta bioquímica (marcadores tumorales y analítica), según métodos de imagen (gammagrafía de receptores de somatostatina, tomografía computarizada y resonancia magnética) y respuesta funcional y de calidad de vida (mediante la Escala de actividad de Karnofsky). Se ha evaluado también la toxicidad del tratamiento. Los resultados obtenidos han sido los siguientes: respuesta bioquímica: el 60% de los pacientes mostraron una normalización de sus niveles de marcadores tumorales, mientras que en el 40% disminuyeron de manera significativa; respuesta en técnicas de imagen: el 85,7% presentaron una respuesta parcial, mientras que el 14,3% mostraron enfermedad estable; mejoría de la calidad de vida: el 100% de los pacientes mostraron una mejoría significativa en la calidad de vida con un incremento de la Escala de actividad de Karnofsky, y en cuanto a la toxicidad: ningún paciente presentó toxicidad aguda o crónica, y el 42,8% de los pacientes presentaron toxicidad subaguda hematológica transitoria. A pesar de tratarse de un estudio preliminar podemos afirmar que el tratamiento con 177Lu-DOTATATE es un tratamiento seguro, con pocos efectos adversos y que consigue una respuesta objetiva en la mayoría de los pacientes. Therapy with radiolabelled somatostatin analogue peptides is a promising new therapy to treat neuroendocrine tumours. The aim of this preliminary study is to present our experience with 177Lu-DOTATATE therapy, and evaluate tolerability and short-term efficacy in patients with tumours expressing somatostatin receptors. A total of 7 patients with metastatic neuroendocrine tumours were treated, each with 4 doses of 177Lu-DOTATATE. The treatment response was evaluated in the form of biochemical response (tumour markers), imaging methods (somatostatin receptor scintigraphy, computed tomography, and magnetic resonance), and functional and quality of life responses using the Karnofsky performance status scale. Treatment toxicity was also evaluated. The results obtained were as follows: Biochemical response: 60% of patients showed tumour marker levels returning to normal, while they decreased significantly in the remaining 40%. Imaging response: 85.7% had a partial response, while 14.3% showed stable disease. All (100%) patients showed a significant improvement in quality of life, with increased Karnofsky scale scores. No patient had acute or chronic toxicity, and subacute transient haematological toxicity was observed in 42.8% of patients. Despite being a preliminary study, it was found that treatment with 177Lu-DOTATATE is a safe treatment with few side effects, and an objective response was achieved in most patients.

      PubDate: 2016-11-28T10:38:50Z
      DOI: 10.1016/j.remn.2016.10.003
       
  • 64Cu-PSMA uptake in meningioma: A potential pitfall of a promising
           radiotracer
    • Authors: F. Calabria; V. Gangemi; D. Gullà; O. Schillaci; G.L. Cascini
      Abstract: Publication date: Available online 22 November 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): F. Calabria, V. Gangemi, D. Gullà, O. Schillaci, G.L. Cascini


      PubDate: 2016-11-28T10:38:50Z
      DOI: 10.1016/j.remn.2016.10.002
       
  • Dr. Julio Barandela Salgado
    • Authors: L.M. Campos Villarino
      Abstract: Publication date: Available online 19 November 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): L.M. Campos Villarino


      PubDate: 2016-11-21T10:29:51Z
      DOI: 10.1016/j.remn.2016.10.001
       
  • Relationship between primary tumour 18F-FDG uptake and immunohistochemical
           and clinical prognostic parameters in breast carcinoma
    • Authors: G.K. Gedik; F. Yilmaz; O. Sari
      Abstract: Publication date: Available online 15 November 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): G.K. Gedik, F. Yilmaz, O. Sari
      Objective The objective of this study was to investigate the relationship between level of 18F-fluorodeoxyglucose (18F-FDG) accumulation in primary breast tumour assessed by positron emission tomography/computed tomography (PET/CT) and histopathological and clinical prognostic factors. Material and methods A retrospective analysis was performed using the medical records of 58 female patients (age range: 31-86 years, mean age: 56) with biopsy of proven breast carcinoma, and who had undergone 18F-FDG PET/CT examination before chemotherapy/surgery. The 18F-FDG uptake of breast tumours was calculated as tumour to background ratio (TBR), which was compared with histopathological and clinical prognostic parameters. Results The histology of the breast tumour in the 58 patients was ductal type in 52 (90%), lobular in 4 (7%), and mucinous in 2 (3%). Tumour size was ≤ 2cm in 31 (53%) patients, and>2cm in 27 (47%). The levels of TBRs were not significantly different between the patients groups with tumours of 2cm or less and greater than 2cm (P =0.131). No significant difference between levels of TBR was observed neither with regards to axillary lymph node involvement (P =0.065) nor in terms of distant metastases (p=0.123). No statistically significant difference was found in levels of TBRs between patients with c-erbB-2 receptor positive and negative ones (P =0.107). Progesterone receptor (PR) expression was observed in 33 patients (57%), and 25 patients (43%) were PR negative. As regards progesterone receptor status, a statistically significant difference was observed in mean TBR levels between patients with and without progesterone receptor expression (P =0.020). Oestrogen receptor expression was positive in 41 (71%) patients, and negative in 17 (29%) patients. The difference in the levels of TBRs between patients with and without oestrogen receptor expression was at the level of significancy (P =0.050). Conclusions It is concluded that 18F-FDG uptake correlates with progesterone negativity of the tumour. However, a significant association with clinical prognostic parameters and level of 18F-FDG uptake levels could not be demonstrated.

      PubDate: 2016-11-21T10:29:51Z
      DOI: 10.1016/j.remn.2016.09.006
       
  • Right atrial metastasis of GIST detected by 18F-FDG PET/CT
    • Authors: D. Albano; M. Bonacina; E. Cossalter; F. Bertagna
      Abstract: Publication date: Available online 12 November 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): D. Albano, M. Bonacina, E. Cossalter, F. Bertagna


      PubDate: 2016-11-14T10:18:34Z
      DOI: 10.1016/j.remn.2016.08.003
       
  • “Pine tree” appearance on 18F-FDG PET/CT MIP image in spinal
           tuberculosis
    • Authors: T. Kumar Jain; A. Sood; R. Kumar Basher; A. Bhattacharya; B. Rai Mittal; A.K. Aggarwal
      Abstract: Publication date: Available online 9 November 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): T. Kumar Jain, A. Sood, R. Kumar Basher, A. Bhattacharya, B. Rai Mittal, A.K. Aggarwal


      PubDate: 2016-11-14T10:18:34Z
      DOI: 10.1016/j.remn.2016.07.001
       
  • 18F-FDG PET/CT of common hepatic duct lymphoepithelioma-like carcinoma
    • Authors: B. Li; Y. Zhang; J. Hou; H. Shi
      Abstract: Publication date: Available online 9 November 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): B. Li, Y. Zhang, J. Hou, H. Shi


      PubDate: 2016-11-14T10:18:34Z
      DOI: 10.1016/j.remn.2016.06.009
       
  • Carney's triad with synchronous breast cancer: 18F-FDG PET/CT imaging
    • Authors: B.D. Nguyen
      Abstract: Publication date: November–December 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular, Volume 35, Issue 6
      Author(s): B.D. Nguyen


      PubDate: 2016-11-07T10:03:52Z
       
  • Hemorrhagic pseudotumors of iliac bones in Noonan syndrome: PET/CT imaging
    • Authors: K.D. Nguyen; B.D. Nguyen
      Abstract: Publication date: Available online 28 October 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): K.D. Nguyen, B.D. Nguyen


      PubDate: 2016-10-31T07:50:15Z
      DOI: 10.1016/j.remn.2016.08.006
       
  • Additional value of hybrid SPECT/CT systems in neuroendocrine tumors,
           adrenal tumors, pheochromocytomas and paragangliomas
    • Authors: K.K. Wong; S. Chondrogiannis; D. Fuster; C. Ruiz; M.C. Marzola; F. Giammarile; P.M. Colletti; D. Rubello
      Abstract: Publication date: Available online 25 October 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): K.K. Wong, S. Chondrogiannis, D. Fuster, C. Ruiz, M.C. Marzola, F. Giammarile, P.M. Colletti, D. Rubello
      The aim of this review was to evaluate the potential advantages of SPECT/CT hybrid imaging in the management of neuroendocrine tumors, adrenal tumors, pheochromocytomas and paragangliomas. From the collected data, the superiority of fused images was observed as providing both functional/molecular and morphological imaging compared to planar imaging. This provided an improvement in diagnostic imaging, with significant advantages as regards: (1) precise locating of the lesions; (2) an improvement in characterization of the findings, resulting higher specificity, improved sensitivity, and overall greater accuracy, (3) additional anatomical information derived from the CT component; (4) CT-based attenuation correction and potential for volumetric dosimetry calculations, and (5) improvement on the impact on patient management (e.g. in better defining treatment plans, in shortening surgical operating times). It can be concluded that SPECT/CT hybrid imaging provides the nuclear medicine physician with a powerful imaging modality in comparison to planar imaging, providing essential information about the location of lesions, and high quality homogeneous images.

      PubDate: 2016-10-31T07:50:15Z
      DOI: 10.1016/j.remn.2016.09.003
       
  • Gammagrafía con 75SeHCAT en la diarrea crónica por malabsorción de
           ácidos biliares
    • Authors: L.M. Mena Bares; E. Carmona Asenjo; M.V. García Sánchez; E. Moreno Ortega; F.R. Maza Muret; M.V. Guiote Moreno; A.M. Santos Bueno; E. Iglesias Flores; J.M. Benítez Cantero; J.A. Vallejo Casas
      Abstract: Publication date: Available online 17 October 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): L.M. Mena Bares, E. Carmona Asenjo, M.V. García Sánchez, E. Moreno Ortega, F.R. Maza Muret, M.V. Guiote Moreno, A.M. Santos Bueno, E. Iglesias Flores, J.M. Benítez Cantero, J.A. Vallejo Casas
      La diarrea crónica es una entidad común en la práctica clínica diaria y supone un deterioro en la calidad de vida de los pacientes. Puede ser el síntoma principal de múltiples etiologías, entre las que se encuentra la malabsorción de ácidos biliares (MAB), que en la población general presenta una prevalencia comparable a la enfermedad celíaca. La MAB ocurre por una alteración en la homeostasis de los ácidos biliares en la circulación enterohepática. Puede aparecer como consecuencia de una disfunción o enfermedad ileal (MAB tipo i), por causas idiopáticas (MAB tipo ii) o asociada con otras entidades gastrointestinales (MAB tipo iii). Entre los diferentes métodos diagnósticos disponibles destacamos la gammagrafía con 75SeHCAT como gold standard debido a sus valores de sensibilidad, especificidad, seguridad y bajo coste. La principal desventaja es que no se encuentra disponible en todos los países, por lo que se han desarrollado otros métodos como la medición sérica de FGF19 y C4 que, sin embargo, presentan una mayor complejidad y coste. El tratamiento de primera línea ante un diagnóstico de MAB es con quelantes de ácidos biliares como la colestiramina, pero presenta baja tolerabilidad y efectos secundarios, que son menores con los nuevos fármacos como el colesevelam. En resumen, la MAB es una entidad común que se encuentra infradiagnosticada e infratratada, por lo que es fundamental establecer un adecuado algoritmo diagnóstico de la diarrea crónica en el que el estudio con 75SeHCAT ocuparía la primera o segunda línea en el diagnóstico diferencial de estos pacientes. Chronic diarrhoea is a common entity in daily clinical practice and it leads to a loss in these patients quality of life. It may be the main symptom of multiple ethiologies including bile acid malabsorption (BAM) which has a comparable prevalence to celiac disease. The BAM results from imbalances in the homeostasis of bile acids in the enterohepatic circulation. It can be a consequence of ileal disease or ileal dysfunction (BAM type i), it can be considered idiopathic or primary (BAM type ii) or associated with other gastrointestinal entities (BAM type iii). Among the different diagnostic methods available, 75SeHCAT study is the primary current method due to its sensitivity, specificity, safety and low cost. The main disadvantage is that it's not available in all countries, so other diagnostic methods have appeared, such as serum measurement of FGF19 and C4, however they are significantly more complex and costly. The first-line treatment of bile acid diarrhoea is bile acid sequestrant, such as cholestyramine, which can be difficult to administer due to its poor tolerability and gastrointestinal side effects. These are less prominent with newer agents such as colesevelam. In summary, the BAM is a common entity underdiagnosed and undertreated, so it is essential to establish a diagnosis algorithm of chronic diarrhoea in which the 75SeHCAT study would be first or second line in the differential diagnosis of these patients.

      PubDate: 2016-10-31T07:50:15Z
      DOI: 10.1016/j.remn.2016.08.005
       
  • 18F-FDG PET/CT and sentinel lymph node biopsy in the staging of patients
           with cervical and endometrial cancer. Role of dual-time-point imaging
    • Authors: M. Mayoral; P. Paredes; B. Domènech; P. Fusté; S. Vidal-Sicart; A. Tapias; A. Torné; J. Pahisa; J. Ordi; F. Pons; F. Lomeña
      Abstract: Publication date: Available online 22 September 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): M. Mayoral, P. Paredes, B. Domènech, P. Fusté, S. Vidal-Sicart, A. Tapias, A. Torné, J. Pahisa, J. Ordi, F. Pons, F. Lomeña
      Objective Definitive staging for cervical (CC) and endometrial cancer (EC) takes place once surgery is performed. The aim of this study was to evaluate the role of PET/CT in detecting lymphatic metastasis in patients with CC and EC using dual-time-point imaging (DPI), taking the histopathological results of sentinel lymph node (SLN) and lymphadenectomy as the reference. Material and methods A prospective study was conducted on 17 patients with early CC, and 13 patients with high-risk EC. The patients had a pre-operative PET/CT, MRI, SLN detection, and lymphadenectomy, when indicated. PET/CT findings were compared with histopathological results. Results In the pathology study, 4 patients with CC and 4 patients with EC had lymphatic metastasis. PET/CT showed hypermetabolic nodes in 1 patient with CC, and 5 with EC. Four of these had metastasis, one detected in the SLN biopsy. Four patients who had negative PET/CT had micrometastasis in the SLN biopsy, 1 patient with additional lymph nodes involvement. The overall patient-based sensitivity, specificity, positive and negative predictive values, and accuracy of PET/CT to detect lymphatic metastasis was 20.0%, 100.0%, 100.0%, 87.9%, and 88.2%, respectively, in CC, and 57.1%, 88.9%, 66.7%, 84.2% and 80.0%, respectively, in EC. DPI showed higher retention index in malignant than in inflammatory nodes, although no statistically significant differences were found. Conclusions PET/CT has low sensitivity in lymph node staging of CC and EC, owing to the lack of detection of micrometastasis. Thus, PET/CT cannot replace SLN biopsy. Although no statistically significant differences were found, DPI may help to differentiate between inflammatory and malignant nodes.

      PubDate: 2016-09-27T11:00:40Z
      DOI: 10.1016/j.remn.2016.07.003
       
  • Hybrid-fusion SPECT/CT systems in parathyroid adenoma: Technological
           improvements and added clinical diagnostic value
    • Authors: K.K. Wong; S. Chondrogiannis; H. Bowles; D. Fuster; N. Sánchez; L. Rampin; D. Rubello
      Abstract: Publication date: Available online 21 August 2016
      Source:Revista Española de Medicina Nuclear e Imagen Molecular
      Author(s): K.K. Wong, S. Chondrogiannis, H. Bowles, D. Fuster, N. Sánchez, L. Rampin, D. Rubello
      Nuclear medicine traditionally employs planar and single photon emission computed tomography (SPECT) imaging techniques to depict the biodistribution of radiotracers for the diagnostic investigation of a range of disorders of endocrine gland function. The usefulness of combining functional information with anatomy derived from computed tomography (CT), magnetic resonance imaging (MRI), and high resolution ultrasound (US), has long been appreciated, either using visual side-by-side correlation, or software-based co-registration. The emergence of hybrid SPECT/CT camera technology now allows the simultaneous acquisition of combined multi-modality imaging, with seamless fusion of 3D volume datasets. Thus, it is not surprising that there is growing literature describing the many advantages that contemporary SPECT/CT technology brings to radionuclide investigation of endocrine disorders, showing potential advantages for the pre-operative locating of the parathyroid adenoma using a minimally invasive surgical approach, especially in the presence of ectopic glands and in multiglandular disease. In conclusion, hybrid SPECT/CT imaging has become an essential tool to ensure the most accurate diagnostic in the management of patients with hyperparathyroidism.

      PubDate: 2016-09-22T10:53:27Z
      DOI: 10.1016/j.remn.2016.07.004
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.197.136.128
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2016